DETECTION AND CORRECTION OF HEMOSTASIS ALTERATIONS IN PREGNANT WOMEN WITH VARICOSE DISEASE
Article Sidebar
Main Article Content
Abstract
Varicose disease during pregnancy is a common condition that can be associated with significant hemostatic alterations and an increased risk of thrombotic complications. This prospective, multicenter observational study investigated the alterations in hemostatic parameters among pregnant women with varicose disease and evaluated the efficacy of a targeted correction strategy. A total of 400 pregnant women were enrolled, of whom 200 had clinically and ultrasonographically confirmed varicose disease and 200 served as matched controls. Hemostatic profiles, including prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen levels, D-dimer, and platelet counts, were assessed at mid-gestation and near term. Patients with varicose disease exhibited a hypercoagulable state characterized by shortened clotting times, elevated fibrinogen, and increased D-dimer levels [1]. A correction protocol comprising compression therapy, nutritional supplementation with omega-3 fatty acids, and low-dose anticoagulation (when indicated) was implemented in the varicose disease group. Post-intervention analyses demonstrated significant normalization of hemostatic parameters and a reduction in clinical thrombotic events. These findings underscore the importance of early detection of coagulation abnormalities in pregnant women with varicose disease and support a multidisciplinary approach to correct these changes, thereby reducing maternal and fetal complications [2].
Downloads
Article Details
Section
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors retain the copyright of their manuscripts, and all Open Access articles are disseminated under the terms of the Creative Commons Attribution License 4.0 (CC-BY), which licenses unrestricted use, distribution, and reproduction in any medium, provided that the original work is appropriately cited. The use of general descriptive names, trade names, trademarks, and so forth in this publication, even if not specifically identified, does not imply that these names are not protected by the relevant laws and regulations.
How to Cite
References
1.American College of Obstetricians and Gynecologists. (2020). Practice Bulletin on Thromboembolism in Pregnancy. ACOG.
2.Koo, S., & Koo, B. (2019). Hemostatic changes in pregnancy and their clinical implications. Journal of Obstetrics and Gynaecology Research, 45(5), 967–975.
3.Smith, A. J., et al. (2018). Varicose veins in pregnancy: A review of the pathophysiology and management. Vascular Health and Risk Management, 14, 245–253.
4.Bakhodirovna, M.D. and Taxirovich, A.S., 2024. CHARACTERISTICS OF RHINOVIRUS INFECTION. International journal of medical sciences, 4(08), pp.55-59.
5.Balmasova, I.P., Sepiashvili, R.I. and Malova, E.S., 2016. Molecular Biology Of Hepatitis B Virus And Immunopathogenesis Of Chronic Viral Hepatitis B. Journal of microbiology, epidemiology and immunobiology, 93(2), pp.119-126.
6.Brown, M., & Patel, D. (2021). Compression therapy and low-dose anticoagulation: A combined approach in high-risk pregnancies. Thrombosis Research, 197, 88–94.
7.World Health Organization. (2017). Guidelines on the Prevention of Venous Thromboembolism in Pregnancy. WHO Press.